These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 19853645)

  • 1. Targeted drug delivery in pancreatic cancer.
    Yu X; Zhang Y; Chen C; Yao Q; Li M
    Biochim Biophys Acta; 2010 Jan; 1805(1):97-104. PubMed ID: 19853645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonviral siRNA delivery systems for pancreatic cancer therapy.
    Aghamiri S; Raee P; Talaei S; Mohammadi-Yeganeh S; Bayat S; Rezaee D; Ghavidel AA; Teymouri A; Roshanzamiri S; Farhadi S; Ghanbarian H
    Biotechnol Bioeng; 2021 Oct; 118(10):3669-3690. PubMed ID: 34170520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic modalities and drug delivery in pancreatic cancer - an ongoing search for improved efficacy.
    Zhang Y; Satoh K; Li M
    Drugs Context; 2012 Dec; 2012():212244. PubMed ID: 24432033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic Cancer: Recent Advances in Nanoformulation-Based Therapies.
    Desai P; Ann D; Wang J; Prabhu S
    Crit Rev Ther Drug Carrier Syst; 2019; 36(1):59-91. PubMed ID: 30789818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposome-based diagnostic and therapeutic applications for pancreatic cancer.
    Raza F; Evans L; Motallebi M; Zafar H; Pereira-Silva M; Saleem K; Peixoto D; Rahdar A; Sharifi E; Veiga F; Hoskins C; Paiva-Santos AC
    Acta Biomater; 2023 Feb; 157():1-23. PubMed ID: 36521673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic cancer: pathobiology, treatment options, and drug delivery.
    Li J; Wientjes MG; Au JL
    AAPS J; 2010 Jun; 12(2):223-32. PubMed ID: 20198462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles.
    Qian C; Wang Y; Chen Y; Zeng L; Zhang Q; Shuai X; Huang K
    Biomaterials; 2013 Aug; 34(26):6175-84. PubMed ID: 23721794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in Nanoparticle-Based Targeted Drug-Delivery Systems Against Cancer and Role of Tumor Microenvironment.
    Ashfaq UA; Riaz M; Yasmeen E; Yousaf MZ
    Crit Rev Ther Drug Carrier Syst; 2017; 34(4):317-353. PubMed ID: 29199588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside.
    Yang F; Jin C; Jiang Y; Li J; Di Y; Ni Q; Fu D
    Cancer Treat Rev; 2011 Dec; 37(8):633-42. PubMed ID: 21330062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for the treatment of pancreatic cancer.
    Van Laethem JL; Marechal R
    Expert Opin Emerg Drugs; 2007 May; 12(2):301-11. PubMed ID: 17604503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapies for Pancreatic Cancer and Hurdles Ahead.
    Aslan M; Shahbazi R; Ulubayram K; Ozpolat B
    Anticancer Res; 2018 Dec; 38(12):6591-6606. PubMed ID: 30504367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted drug delivery systems for pancreatic cancer.
    Khare V; Alam N; Saneja A; Dubey RD; Gupta PN
    J Biomed Nanotechnol; 2014 Dec; 10(12):3462-82. PubMed ID: 26000366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-targeted liposomes for cancer treatment.
    Sapra P; Tyagi P; Allen TM
    Curr Drug Deliv; 2005 Oct; 2(4):369-81. PubMed ID: 16305440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.
    Ohman KA; Hashim YM; Vangveravong S; Nywening TM; Cullinan DR; Goedegebuure SP; Liu J; Van Tine BA; Tiriac H; Tuveson DA; DeNardo DG; Spitzer D; Mach RH; Hawkins WG
    Oncotarget; 2016 Jun; 7(23):33529-41. PubMed ID: 27244881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
    Lang J; Zhao X; Wang X; Zhao Y; Li Y; Zhao R; Cheng K; Li Y; Han X; Zheng X; Qin H; Geranpayehvaghei M; Shi J; Anderson GJ; Hao J; Ren H; Nie G
    ACS Nano; 2019 Feb; 13(2):2176-2189. PubMed ID: 30676731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Perspectives on Novel Drug Carrier Systems and Therapies for Management of Pancreatic Cancer: An Updated Inclusive Review.
    Bhosale RR; Gangadharappa HV; Gowda DV; Osmani RAMA; Vaghela R; Kulkarni PK; Sairam KV; Gurupadayya B
    Crit Rev Ther Drug Carrier Syst; 2018; 35(3):195-292. PubMed ID: 29953347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review.
    Bhosale RR; Gangadharappa HV; Hani U; Ali M Osmani R; Vaghela R; Kulkarni PK; Koganti VS
    Curr Drug Targets; 2017; 18(11):1233-1249. PubMed ID: 27296312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic Cancer Therapy Review: From Classic Therapeutic Agents to Modern Nanotechnologies.
    Rebelo A; Molpeceres J; Rijo P; Reis CP
    Curr Drug Metab; 2017; 18(4):346-359. PubMed ID: 28155623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in Nanoparticle-Mediated Diagnosis and the Treatment of Pancreatic Cancer.
    Nedelcu A; Mocan T; Grapa C; Mocan L
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.